domain [Thakore et al., 2015]; upregulation using a dCas9 fusion to the tetrameric VP16 transcription activator domain [VP64] [Kearns et al., 2014, Maeder et al., 2013] or the tripartite activator, VP64-p65-Rta (VPR) [Chavez et al., 2015, Chavez et al., 2016]), in three different hiPSC-derived neural cell types (NPCs, neurons, and astrocytes) (Figure 1), using hiPSCs reprogrammed from three unique donors (Table S1), we describe the efficacy and variability of dCas9-protein fusion-based transcriptional modulation in hiPSC-based studies.
